# OnCo record c-post (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/c-post/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "c-post", "NCT03969004" ;
  schema:name "C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)"@en ;
  schema:alternateName "C-POST"@en, "Cemiplimab POST-operative trial"@en ;
  schema:description "This is the first trial to show that a drug given after surgery and radiotherapy stops the most dangerous skin squamous cancers coming back. Two years on, 87 out of 100 treated were still free of the cancer, against 64 out of 100 given a dummy."@en ;
  schema:url <https://onco.cc/trials/c-post/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03969004>, <https://doi.org/10.1056/NEJMoa2502449>, <https://pubmed.ncbi.nlm.nih.gov/40454639/> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/cutaneous-scc/>, <https://onco.cc/cancers/advanced-cutaneous-scc/>, <https://onco.cc/cancers/skin-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/cemiplimab/> ;
  onco:companies <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/sanofi/> ;
  onco:terms <https://onco.cc/terms/perineural-invasion/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/radiotherapy-for-skin-cancer/>, <https://onco.cc/terms/tmb/> ;
  onco:trials <https://onco.cc/trials/empower-cscc-1/>, <https://onco.cc/trials/trog-05-01/>, <https://onco.cc/trials/neoadjuvant-cemiplimab-cscc/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/> .